Compare Repligen Corporation Common Stock (RGEN) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Workday Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Workday Inc trades at $188.91 (market cap $44.83B). The key difference: Workday Inc is far larger — about 4× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Workday Inc for 38 Days on average.
| RGEN | WDAY | |
|---|---|---|
Market Cap | $11.14B | $44.83B |
Volume | 1,259,263 | 2,168,736 |
Sector | Health | Technology |
52-Week High | $194.57 | $245.67 |
52-Week Low | $102.87 | $112.55 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $11.02B | $45.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Workday (WDAY) trades at $188.77, up 0.28% today, with a bullish technical signal from moving averages and a consensus analyst price target of $203.19. The company has beaten earnings estimates for the last three quarters, with Q3 2026 EPS expected at $2.74. Revenue grew to $8.45 billion in 2025, and recent news highlights AI product launches and strategic partnerships, though layoffs and a fraud investigation present headwinds.
WDAY offers growth potential driven by AI integration and expanding market presence, but faces risks from competitive pressures and execution challenges. The stock's valuation multiples are elevated, requiring sustained earnings growth to justify current levels. Investor sentiment is mixed amid operational adjustments and legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
